Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Current Assets (2023 - 2025)

Historic Current Assets for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $401.8 million.

  • Monte Rosa Therapeutics' Current Assets rose 5995.45% to $401.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $401.8 million, marking a year-over-year increase of 5995.45%. This contributed to the annual value of $377.4 million for FY2024, which is 5978.87% up from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Current Assets is $401.8 million, which was up 5995.45% from $299.5 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Current Assets high stood at $401.8 million for Q3 2025, and its period low was $182.9 million during Q3 2023.
  • For the 3-year period, Monte Rosa Therapeutics' Current Assets averaged around $273.4 million, with its median value being $251.2 million (2024).
  • As far as peak fluctuations go, Monte Rosa Therapeutics' Current Assets tumbled by 1726.0% in 2024, and later surged by 6694.47% in 2025.
  • Monte Rosa Therapeutics' Current Assets (Quarter) stood at $236.2 million in 2023, then soared by 59.79% to $377.4 million in 2024, then rose by 6.46% to $401.8 million in 2025.
  • Its Current Assets stands at $401.8 million for Q3 2025, versus $299.5 million for Q2 2025 and $332.3 million for Q1 2025.